Despite a surge in FDA-cleared radiology AI tools, very few qualify for reimbursement due to lack of supporting clinical studies.
Key Details
- 1Radiology comprises roughly 80% of all FDA-cleared medical AI algorithms.
- 2Only one CPT category 1 payment code for newer AI tools exists today; a second will be added in January 2026.
- 3Both reimbursement codes are specific to cardiac imaging AI applications.
- 4Hundreds of approved algorithms lack reimbursement due to insufficient clinical evidence of patient benefit.
- 5Experts attribute the problem to a disconnect between regulatory clearance and payment policy.
Why It Matters
Without reimbursement, the financial incentives for clinical adoption of imaging AI are limited, slowing broader deployment of these technologies. Bridging the gap between regulatory approval and payment is critical for real-world impact of AI in radiology.
Source
Radiology Business
Related News
•HealthExec
Mayo Clinic Sued Over Alleged AI Improprieties and Whistleblower Retaliation
A former Mayo Clinic research director sues the institution, alleging retaliation after raising concerns about improper AI use affecting patient safety and data integrity.
•Radiology Business
Use of Generative AI in Radiology Manuscripts Surges, Raising Integrity Concerns
Disclosure of generative AI usage in radiology manuscript writing has more than doubled in recent years, prompting editorial caution about scientific integrity.
•Radiology Business
Majority of Patients Want Disclosure When AI Used in Imaging
A new survey finds that nearly all patients want to be informed when AI is utilized in medical imaging interpretation.